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Purpose. To compare the ocular hypotensive eﬀect of tafluprost with prostaglandin analogues (PGAs) in glaucoma patients.
Methods. 89 primary open-angle glaucoma patients treated with bimatoprost, latanoprost, or travoprost for at least 3 months
complaining for ocular discomfort were switched to tafluprost. IOP was assessed at baseline and 3 months after switching the
therapy by daily curve. Primary outcome was to compare the mean daily IOP of tafluprost with PGAs. Results. The mean daily
IOP was 16 ± 2.1 and 16.6 ± 2.0mm Hg at baseline and after switching to tafluprost, respectively (P > 0.05). When analysis was
carried out between tafluprost and each previous PGAs, the comparison between latanoprost and tafluprost and travoprost and
tafluprost did not show any statistically significant diﬀerence in mean daily IOP and at each time point. The comparison between
bimatoprost and tafluprost showed a statistically significant diﬀerence in mean daily IOP (P < 0.05) and at each time point
(P < 0.05). Conclusions. After 3 months of switching tafluprost showed an overall IOP lowering eﬀect similar to others PGAs.
When each PGA was compared with tafluprost, bimatoprost showed to provide a statistically significant additional IOP lowering
eﬀect.
1. Introduction
Intraocular pressure (IOP) is known to be the main risk fa-
ctor for development and progression of glaucoma [1, 2].
Lowering intraocular pressure is the only evidence-based
method for treating glaucoma, reducing the risk of visual
field progression from 13% to 19% per 1mmHg of IOP low-
ering [3, 4].
According to the EuropeanGlaucoma Society Guidelines,
topical monotherapy is the first step in the medical manage-
ment [1].
Among the many topical hypotensive medications, pros-
taglandin analogues (PGAs) are proved to be the most potent
in lowering IOP and with very few systemic side eﬀects [5, 6].
PGAs were first proposed for glaucoma treatment by
Camras et al. in 1977 [7]. Nowadays, derivatives of pros-
taglandin F2α, that is, latanoprost, travoprost, unoprostone,
prostamide, and bimatoprost are commercially available. In
van der Valk’s meta-analysis, latanoprost reduced IOP by
28%–31% from baseline, travoprost by 29%–31%, and bi-
matoprost by 28%–33%. Latanoprost and travoprost are
selective prostanoid FP receptor agonists, and by binding to
these receptors they exert their IOP-lowering eﬀect [7, 8].
Bimatoprost is a prostamide, with a molecular mecha-
nism of action not clearly understood [9, 10].
All these compounds decrease IOP by increasing aqueous
outflow, mainly through the uveoscleral (unconventional)
route [11].
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PGAs appear to regulate matrix metalloproteinases
(MMP) and tissue inhibitors of matrix metalloproteinases
(TIMP) to modulate trabecular outflow resistance. MMPs
are neutral zinc-dependent endoproteinases involved with
normal and pathologic remodeling of extracellular matrix
[12].
Increased expression of MMP-1, -3, -17, and -24 and
TIMP-2, -3, -4 may lead to hydrolysis of collagen types I and
III (MMP-1), collagen IV and fibronectin (MMP-2), and col-
lagen types III, IV, fibronectin and laminin (MMP-3), re-
sulting in the widening of the connective tissue-filled spaces
among the ciliary muscle bundles and loss of trabecular
meshwork (TM) extracellular matrix, hence increased out-
flow [11].
A new prostanoid receptor analogue in a preservative-
free formulation, tafluprost, has been authorized for medical
treatment of glaucoma and ocular hypertension.
Tafluprost diﬀers from the other prostanoids available on
the market for the presence of two fluorine atoms at the
carbon-15 position, instead of the hydroxyl group present
in latanoprost, travoprost, and bimatoprost [13]. Its aﬃnity
for the human prostanoid FP receptor is 12 times that of the
carboxylic acid in latanoprost [14].
Glaucomatous patients often need to use topical therapy
for many years, and, in order to promote compliance,
adverse events and side eﬀects should be minimized. Among
these side eﬀects, ocular surface disorders attributable to
the drug itself or to drug preservatives are relatively com-
mon [15, 16].
The adverse influence of preservative-containing topical
antiglaucomamedications on cells and tissues on the eye sur-
face is well documented, both in vitro and in vivo studies
[17, 18].
Benzalkonium chloride (BAK) is the most commonly
used preservative in eye drops. It has already been found that
this compound exerts cytotoxic (proapoptotic and prone-
crotic) eﬀects on the ocular surface and trabecular meshwork
cells [19, 20].
Solutions preservative-free, containing lower BAK con-
centrations or alternative preservatives, were introduced into
topical glaucoma therapy to minimize side eﬀects. Among
the widely used prostaglandin analogues, only tafluprost is
actually available in a preservative-free formulation. A pre-
servative-free solution of tafluprost showed reduced toxicity
in human conjunctival epithelial cell lines when compared
with preserved latanoprost, travoprost, and bimatoprost
[21].
Despite several studies concerning its eﬃcacy [22, 23],
safety [24], and tolerability [25], the IOP lowering eﬀect of
tafluprost, as compared with the other prostaglandin ana-
logues is not well established.
The purpose of this study was to assess the ocular hy-
potensive eﬀect and the tolerability of tafluprost (0.0015%)
in glaucoma patients previously treated with latanoprost
(0.005%), travoprost (0.004%), or bimatoprost (0.03%)
complaining for ocular discomfort. To the best of our knowl-
edge, this is the first study comparing tafluprost to all the
other PGAs commercially available.
2. Methods
This prospective clinical study was carried out at the Eye
Clinic of the University of Milan, San Giuseppe Hospital,
Milan, Italy, and it was approved by the local Ethical Com-
mittee conducted according to ICH/GCP guidelines. Patients
of 18 years or older who fulfilled the eligibility criteria were
recruited consecutively during routine visits and included in
the study.
2.1. Inclusion Criteria. Patients with diagnosis of primary
open-angle glaucoma based on the European Glaucoma So-
ciety Guidelines criteria, [5] treated with latanoprost, travo-
prost, or bimatoprost monotherapy for at least 3 months,
complaining for ocular surface discomfort with baseline IOP
less than 21mmHg at all-time point with target IOP reached
as set by the treating physician, were considered for the study.
2.2. Exclusion Criteria. Exclusion criteria included closed or
barely open anterior chamber angle, or history of acute angle
closure ocular trauma, history of ocular surgery, argon laser
trabeculoplasty, ocular inflammation or infection occurring
within 3 months before the baseline visit, neovascular glau-
coma, history of refractive surgery, inability to adhere to the
treatment and visit plan, other abnormal condition, or symp-
tom preventing the patient from entering the trial, according
to the investigator’s judgment.
2.3. Study Plan. Patients treated with latanoprost, travo-
prost, or bimatoprost monotherapy for at least 3 months,
IOP less than 21mmHg, target IOP reached with ocular sur-
face discomfort were enrolled in the study. At the baseline
visit, a medical history was taken for all the subjects. All the
subjects underwent a complete ophthalmic examination in-
cluding anterior segment biomicroscopy and fundus exami-
nation, refraction and measurement of best-corrected visual
acuity (BCVA) by means of Snellen chart. A masked operator
(SR) measured IOP at 8 AM, 11AM, 2 PM, 5 PM, and 8 PM
by Goldmann applanation tonometry. If both eyes fulfilled
the eligibility criteria, one eye was randomly selected for the
study.
Patients were switched to tafluprost monotherapy with-
out washout between the treatments. Assessment of IOP and
tolerability were carried out 3-month after switching the
therapy by the same masked operator (SR). The investigator
could choose to have a nonscheduled safety visit between
the scheduled visit. IOP mean value at each time point was
calculated as a mean of three IOP diurnal curves carried out
within three weeks at baseline and after 3 months.
2.4. Study Outcomes. The primary outcome was to compare
the mean diurnal IOP from the daily curve after 3 months of
tafluprost treatment compared to preservative prostaglandin
analogue (latanoprost, travoprost, and bimatoprost). Sec-
ondary outcome was to compare the diurnal mean IOP of
the tafluprost treatment after 3 months with each previous
preservative PGAs treatment group asmean IOP and for each
time point separately (8 AM, 11AM, 2 PM, 5 PM, 8 PM).
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2.5. Clinical Tolerability Assessments. Best-corrected visual
acuity (BCVA) bymeans of Snellen chart, biomicroscopy, and
ophthalmoscopy were recorded at the baseline visit and at
each follow-up visit. Any kind of adverse event was recorded.
Change of conjunctival hyperemia was recorded at the slit
lamp using a standard scale ranging from 0 to 3 (where 0 is
none, 1 is mild, 2 is moderate, and 3 is severe) with the help of
a standardized photographic chart [26]. Superficial keratitis,
defined as the presence of small circular epithelial erosion
in the cornea, was also graded as none, mild, moderate, and
severe (none: no staining; mild: rare stained erosion localized
close to the lid margins; moderate: rare stained erosion loca-
lized in the 4 quadrants; diﬀuse: diﬀuse stained erosion in-
volving the 4 quadrants).
2.6. Analysis. Data are presented as mean and 95% confi-
dence intervals for continuous variables and frequencies for
categorical variable. For the IOP recording, the mean values
of 2 measurements at each time point were used in the calcu-
lations. If both eyes fulfilled the eligibility criteria, only one
eye was randomly selected. An intent-to-treat approach was
used to analyze the IOP variables. Categorical variables such
as proportions and tolerability variable were analyzed using
the Pearson chi-square test of Fisher exact test as appropriate.
Formal sample size was calculated in order to assess
the diﬀerence between treatments. Assuming Δ 2.3mmHg
(based on previously published data) [27] and using the
formula:
n =
[
Φ−1(α/2) +Φ−1
(
β
)]2
σ2
Δ2
, (1)
where α = 0.05 and 1 − β = 0.80, a sample of 85 patients
was needed to ensure a 95% chance of detecting a diﬀerence
between the diﬀerent treatments groups.
3. Results
A total of 91 patients were enrolled in this study, and 89
(mean age 64.7± 10.4) were included in the analysis (29 pa-
tients were under latanoprost, 28 under travoprost, and 32
under bimatoprost). Two patients were lost to followup with-
out performing any follow-up visit and were excluded from
the analysis. During the study we did not observe any adverse
events.
3.1. Primary Outcome. Table 1 reports the mean daily IOP
at baseline and after 3 months of treatment with tafluprost.
After 3 months of treatment, mean daily IOP was not
statistically diﬀerent significantly compared with the baseline
(+0.6mmHg, P > 0.05). No interaction between drug and
treatment sequence was detected, indicating no carry-over
eﬀects between drugs.
Figure 1 reports the mean IOP value for each time point
from the daily curve of tafluprost and PGAs treatment group.
For each time point, separately, no diﬀerences were detected
in mean IOP between the two groups (15.4± 2.4 versus 16±
2.3 at 8:00 AM, 15.6±2.3 versus 16.1±2.4 at 11 AM, 16.0±2.4
versus 16.5±2.4 at 2 PM, 16.1±1.8 versus 16.8±2.1 at 5 PM,
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Figure 1: Graph showing IOP at each time point of the daily curve
at baseline (PGAs) and after switching to tafluprost. ∗P > 0.05 from
the comparison of tafluprost time point with the corresponding
PGAs time point. (Curve of PGAs are prestudy, whereas curve of
tafluprost is after dosing.)
16.7 ± 2.6 versus 17.4 ± 1.8 at 8 PM, P > 0.05 for each time
point).
Globally, the incidence of local adverse events was sim-
ilar in both treatments; mean conjunctival hyperemia was
1.2±0.8 with preservative PGAs, and 1.0±0.6 with tafluprost
(P = 0.06), mean punctuate keratitis was 0.8±0.6 with PGAs,
and 0.8± 0.6 with tafluprost (P = 0.2).
In 75% of the patients, there was an improvement of
ocular discomfort, in 21% of patients ocular discomfort was
unchanged, and in 4% there was a worsening of ocular symp-
toms.
3.2. Secondary Outcome. Figure 2 reports the comparison
among themean IOP value for each time point from the daily
IOP curve of the four treatment groups. Comparing latano-
prost to tafluprost treatment, no diﬀerences were found in
mean IOP (16.5±2.3 versus 16.6±2.0, P = 0.85) and at each
time point (15.9±2.6 versus 16.0±2.3 at 8:00 AM, 15.6±2.3
versus 16.1 ± 2.4 at 11 AM, 16.0 ± 2.4 versus 16.5 ± 2.4 at
2 PM, 16.1± 1.8 versus 16.8± 2.1 at 5 PM, 16.7± 2.6 versus
17.4± 1.8 at 8 PM, P > 0.05 for each time point).
No diﬀerences were found in conjunctival hyperemia and
punctuate keratitis between the two groups (P = 0.8 and P =
0.9, resp.).
Comparing travoprost to tafluprost treatment, no diﬀer-
ences were found in mean IOP (15.9± 2.5 versus 16.6± 2.0,
P = 0.15) and at each time point (15.3±2.5 versus 16.0±2.3
at 8:00 AM, 15.5± 2.5 versus 16.1± 2.8 at 11 AM, 16.1± 2.8
versus 16.5±2.4 at 2 PM, 16.1±1.9 versus 16.8±2.1 at 5 PM,
16.5 ± 2.7 versus 17.4 ± 1.8 at 8 PM, P > 0.05 for each time
point).
No diﬀerences were found in conjunctival hyperemia and
punctuate keratitis between the two groups (P = 0.1 and P =
0.3, resp.).
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Table 1: Mean daily IOP at baseline and after 3 months of treatment with tafluprost.
Baseline IOP After 3 months of tafluprost Mean IOP change Mean % IOP change P value
Latanoprost, travoprost, or
bimatoprost treatment
16±2.1mmHg 16.6± 2.0mmHg +0.6mmHg +3.75% >0.05
8 am 11 am 14 pm 17 pm 20 pm
Time point
18
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17
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P = 0.04P = 0.04
P = 0.02
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Figure 2: Graph showing IOP at each time point of the daily curve
of each drug group. ∗P > 0.05 from the comparison of tafluprost
time point with the corresponding latanoprost and travoprost time
point. ∗∗Values from the comparison between tafluprost and
bimatoprost of each time point of the daily curve. (Curve of lat-
anoprost, travoprost, and bimatoprost are prestudy, whereas curve
of tafluprost is after dosing.)
Comparing bimatoprost to tafluprost treatment a statisti-
cally significant diﬀerence was found in mean IOP (15.6±1.8
versus 16.6±2.0, P = 0.01) with a mean increase of 1mmHg
of IOP.
A significant diﬀerence in IOP was found at each time
point (15.0 ± 2.4 versus 16.0 ± 2.3 at 8:00 AM, 15.1 ± 1.7
versus 16.1 ± 2.4 at 11 AM, 15.5 ± 2.0 versus 16.5 ± 2.4 at
2 PM, 15.7± 1.6 versus 16.8± 2.1 at 5 PM, 16.5± 2.4 versus
17.4± 1.8 at 8 PM, P < 0.05 for each time point).
The severity of conjunctival hyperemia and punctuate
keratitis was higher with bimatoprost compared to tafluprost
(1.3 ± 0.9 versus 1.0 ± 0.6, P = 0.02 for conjunctival hyper-
emia and 0.9 ± 0.7 versus 0.7 ± 0.6, P = 0.04 for punctuate
keratitis).
4. Discussion
This prospective study aims to compare the IOP lowering
eﬀect of tafluprost with other PGAs in patients with glau-
coma, with signs and symptoms of ocular discomfort. Pub-
lished studies suggest that the IOP lowering eﬀect of ta-
fluprost is similar to other PGAs with a better local safety
profile due to the absence of BAK [14, 22, 24, 25]. Several
study has been published about safety and eﬃcacy profile of
tafluprost in vitro [19, 21, 23] and in animal models [7, 12,
14, 22, 25, 26], but few studies analyse the IOP lowering eﬀect
in a clinical setting in patients with glaucoma and ocular
hypertension [28–32].
The primary outcome of this study was to compare the
IOP lowering eﬀect of tafluprost with all other BAK pre-
served PGAs.
After 3 months of treatment the mean daily IOP was
not statistically significant diﬀerent compared with preserved
PGAs.
The comparison among the single PGAs and tafluprost
showed a comparable eﬃcacy between latanoprost and ta-
fluprost (P = 0.85) and between travoprost and tafluprost
(P = 0.15). The mean daily IOP and the IOP at any time
point did not show any significant diﬀerence.
The bimatoprost group showed a statistically lower mean
IOP, as compared to tafluprost (P = 0.01), and the IOP
lowering eﬀect was statistically greater at any time point of
the diurnal IOP curve.
The analysis of the ocular surface disorders showed no
statistically diﬀerence between latanoprost and tafluprost
and between travoprost and tafluprost. Bimatoprost showed
to induced a slightly higher conjunctival hyperemia and
punctuate keratitis compared to tafluprost (P < 0.05).
Only few published studies compared tafluprost with
other PGAs [28–32]. Most of them compare tafluprost with
latanoprost [30, 31, 33]. There is only one study comparing
tafluprost with travoprost [28] and none with bimatoprost.
In a recently published study [28] comparing eﬃcacy of
tafluprost with travoprost in patients with glaucoma or ocu-
lar hypertension, the authors found a statistically significant
greater IOP lowering eﬃcacy with travoprost compared to
tafluprost (16.9mmHg versus 17.5mmHg, resp., P = 0.01),
with a similar safety profile for both the treatments.
Our study involved only glaucoma patients, whereas
glaucoma and ocular hypertension patients were enrolled
in Schnober study [34]. The diﬀerent population involved
could explain the diﬀerent results.
In the study by Mochizuki et al. [28], the comparison
between tafluprost and latanoprost in a group of healthy vol-
unteers showed a statistically greater IOP reduction with ta-
fluprost. In this study tafluprost was associated with a higher
rate of conjunctival hyperemia.
Uusitalo et al. [29] investigated the eﬃcacy of tafluprost
in patients treated with latanoprost exhibiting ocular surface
side eﬀects. 158 patients were switched from latanoprost to
tafluprost. After 12 weeks, tafluprost maintained the IOP at
the same value as latanoprost baseline (16.4 ± 2.7mmHg
versus 16.8 ± 2.5mmHg, resp.) with a decrease in subjective
symptoms and objective signs.
Another study by Traverso et al. [30] reports the IOP low-
ering eﬃcacy of tafluprost in patients previously treated with
latanoprost. A preservative formulation of tafluprost was
used in this trial. The lowering eﬀect at 24 months was
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−7.1mmHg and −7.7mmHg in tafluprost and latanoprost
group, respectively. Although a slightly larger IOP lowering
eﬀect of latanoprost, the ANOVA test showed a noninferior-
ity of tafluprost to latanoprost.
Eﬃcacy of tafluprost was compared with latanoprost in
glaucoma and ocular hypertension patients in a recent pub-
lished randomized, controlled study [31]. The mean IOP
reduction was −9.7/−3.3mmHg in the tafluprost group and
−8.8± 4.3mmHg in the latanoprost group, respectively. The
diﬀerence was not significantly diﬀerent, and the author con-
cluded that both tafluprost and latanoprost have a compara-
ble eﬀect on IOP lowering eﬀect.
In agreement with published studies conducted with
glaucoma patients, we found a similar eﬃcacy of tafluprost
compared to latanoprost. In the Mochizuki study, healthy
patients were enrolled. The diﬀerent results of this study are
likely to depend on the diﬀerent population.
Hommer [31] recently published a large series of 544
patients with glaucoma or ocular hypertension treated with
preserved eye drops and poor IOP control or poor local tol-
erance. In these patients previous medications were changed
with tafluprost. Previous therapy was monotherapy, fixed
and nonfixed combination. 45 patients were naı¨ve to treat-
ment. In this heterogeneous group of patients tafluprost
showed to provide a further IOP decrease with an overall re-
duction of IOP in all patients from 19.4 ± 5.0mmHg at
baseline to 15.3 ± 3.5mmHg at 12 weeks. Author found an
improvement in signs and symptoms related to ocular sur-
face inflammation after switching with tafluprost.
Unlike the data from Hommer study, we did not found
any additional IOP lowering eﬀect of tafluprost compared to
other medications. This could be partially explained by the
heterogeneous population enrolled in this study.
According to other studies [8, 28, 32] bimatoprost
showed to be the most eﬀective prostanoid analogue in this
series of patients.
The decrease in ocular inflammation signs and symp-
toms has been detected in this study only comparing taflu-
prost with bimatoprost. The safe profile of the tafluprost
showed in our study is consistent with published data about
in vivo and in vitro safety of the unpreserved eye drops [19–
22, 25].
The lack of the washout between treatments may be a
limitation of the study. Nevertheless, the IOP lowering eﬀect
was evaluated 3 months after the switch of the therapy: this
should be considered a suﬃcient time for the complete wash
out of previous treatments. Other limitation is the short fol-
lowup that makes challenging to identify any long-term eﬃ-
cacy and safety diﬀerences between diﬀerent PGAs. The sam-
ple size of the study was calculated for the first outcome and
is underestimated for the comparison between each group
of PGAs and tafluprost. Prospective, randomized, possibly
multicenter study with a larger sample size it will be needed
to better clarify the long-term eﬃcacy and safety profile of
this new unpreserved PGA.
In conclusion, this is the first study comparing the IOP
lowering eﬃcacy of the all commercially available BAK pre-
served PGAs (latanoprost 0.005%, travoprost 0.004%, bima-
toprost 0.03%) with the new unpreserved PGA (tafluprost
0.0015%). Tafluprost demonstrated a IOP lowering eﬀect
similar to others PGAs and after 3 months of therapy with
tafluprost the mean IOP showed no diﬀerence between ta-
fluprost and BAK preserved PGAs.
Tafluprost showed, towards other PGAs, comparable
eﬃcacy and a safe profile. Furthermore in this study bimato-
prost seems to provide a statistically significant additional
IOP lowering eﬀect compared to patients treated with taflu-
prost.
Disclosure
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